Testing product and process intermediates alone is helpful, but does not provide a complete solution to viral safety. This article proposes integrated solutions for systemic and proactive viral risk mitigation.
Mark Plavsic
Advertisement
Articles by Mark Plavsic
The authors investigate the sufficiency of high-temperature short-time treatment in inactivate mouse minute virus contamination.
Advertisement
Latest Updated Articles
Modeling the Efficacy of HTST for Inactivating Mouse Minute VirusPublished: April 1st 2016 | Updated:
An Integrated Approach to Ensure the Viral Safety of BiotherapeuticsPublished: May 1st 2016 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Regulatory Challenges for Global Manufacturing of Vaccines
2
AI-Driven Organ-on-Chip Platforms Are Changing the Game in Bio/Pharma R&D
3
EU Biopharma Strategy: Scaling Up to Tackle Funding Gaps and Drive Innovation
4
RNAnalytics’ Viktoria Enkmann Ponders Nanoparticle Characterization Advances at CPHI Frankfurt: Part One
5
